Although DNA-based molecular techniques are the gold standard to define BRAF mutational status, BRAF ICC was recently introduced as a rapid test to evaluate the presence of BRAF V600E mutation, demonstrating high diagnostic performance in histological samples [11,12,13,14]. This evidence concerns the gene BRAF and intrahepatic cholangiocarcinoma.